Format

Send to

Choose Destination
Int J Cancer. 2016 Nov 1;139(9):1949-57. doi: 10.1002/ijc.30250. Epub 2016 Jul 18.

Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study.

Author information

1
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
2
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
3
Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA.
4
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
5
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD.
6
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA.
7
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA.
8
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Abstract

Recent epidemiologic evidence has emerged to suggest that use of glucosamine and chondroitin supplements may be associated with reduced risk of colorectal cancer (CRC). We therefore evaluated the association between use of these non-vitamin, non-mineral supplements and risk of CRC in two prospective cohorts, the Nurses' Health Study and Health Professionals Follow-up Study. Regular use of glucosamine and chondroitin was first assessed in 2002 and participants were followed until 2010, over which time 672 CRC cases occurred. Cox proportional hazards regression was used to estimate relative risks (RRs) within each cohort, and results were pooled using a random effects meta-analysis. Associations were comparable across cohorts, with a RR of 0.79 (95% CI: 0.63-1.00) observed for any use of glucosamine and a RR of 0.77 (95% CI: 0.59-1.01) observed for any use of chondroitin. Use of glucosamine in the absence of chondroitin was not associated with risk of CRC, whereas use of glucosamine + chondroitin was significantly associated with risk (RR: 0.77; 95% CI: 0.58-0.999). The association between use of glucosamine + chondroitin and risk of CRC did not change markedly when accounting for change in exposure status over follow-up (RR: 0.75; 95% CI: 0.58-0.96), nor did the association significantly vary by sex, aspirin use, body mass index, or physical activity. The association was comparable for cancers of the colon and rectum. Results support a protective association between use of glucosamine and chondroitin and risk of CRC. Further study is needed to better understand the chemopreventive potential of these supplements.

KEYWORDS:

chemoprevention; chondroitin; colorectal cancer; epidemiology; glucosamine

PMID:
27357024
PMCID:
PMC4990485
DOI:
10.1002/ijc.30250
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center